Pharma
Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval
- January 27, 2023 07:24 AM CET | Reuters

287 (Adds details in paragraphs 3 and 4) PARIS, Jan 27 (Reuters) - Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for
Argenx Receives Notification Of PDUFA Date Extension For SC Efgartigimod
- January 27, 2023 07:10 AM CET
- Reuters
Sanofi/Regeneron: Dupixent wins new stage of EU regulatory approval
- January 27, 2023 07:08 AM CET
- Reuters
Novacyt Cash Position At Dec. 31 Was GBP 87.0 Mln
- January 26, 2023 08:06 AM CET
- Reuters

Gensight Biologics End-Dec Cash Position At EUR 10.6 Mln
- January 26, 2023 07:38 AM CET | Reuters
Jan 26 (Reuters) - Gensight Biologics SA: * GENSIGHT BIOLOGICS REPORTS CASH POSITION AS OF DECEMBER 31, 2022, FY 2022 REVENUES AND PROVIDES BUSINESS UPDATE * GENSIGHT BIOLOGICS' CASH AND CASH
Read More...
Lysogene Announces Conversion Of Safeguard Proceedings Into Reorganization Proceedings
- January 25, 2023 08:08 AM CET | Reuters
Jan 25 (Reuters) - Lysogene SA: * LYSOGENE: CONVERSION OF THE SAFEGUARD PROCEEDINGS INTO REORGANIZATION PROCEEDINGS * THIS REQUEST WAS EXAMINED AND APPROVED BY COMMERCIAL COURT OF NANTERRE AT HEARING
Read More...
Poxel Receives Orphan Drug Designation From EC For PXL770, PXL065
- January 25, 2023 07:32 AM CET | Reuters
Jan 25 (Reuters) - Poxel SA: * POXEL RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR PXL770 AND PXL065 FOR TREATMENT OF ADRENOLEUKODYSTROPHY * POXEL RECEIVES ORPHAN DRUG DESIGNATION
Read More...
Innate Pharma: Hart-Scott-Rodino Clearance Regarding Expansion Of Collaboration With Sanofi On NK Cell Engagers
- January 25, 2023 07:02 AM CET | Reuters
Jan 25 (Reuters) - Innate Pharma SA: * ANNOUNCES HART-SCOTT-RODINO CLEARANCE REGARDING EXPANSION OF ITS COLLABORATION WITH SANOFI ON NK CELL ENGAGERS * ANNOUNCED TODAY EXPIRATION OF WAITING PERIOD
Read More...
Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic
- January 24, 2023 06:15 PM CET | Reuters
Jan 24 (Reuters) - Medincell SA: * INITIATION OF THE PHASE 3 STUDY FOR THE SECOND LONG-ACTING INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY (PROGRAM MDC-TJK) * PHASE 3 STUDY CONDUCTED IN U.S.
Read More...
Neovacs: Commits To Project To Transform Pharnext's Legal Structure
- January 24, 2023 08:35 AM CET | Reuters
Jan 24 (Reuters) - Neovacs SA: * NEOVACS SA - MADE COMMITMENT ALONGSIDE PHARNEXT S.A. AS PART OF THE PROJECT TO TRANSFORM LATTER INTO SOCIETE EN COMMANDITE PAR ACTIONS (S.C.A.). Source text:
Read More...
Advicenne FY Sales Up At €3.7 Million
- January 24, 2023 07:03 AM CET | Reuters
Jan 24 (Reuters) - Advicenne SA: * ADVICENNE REPORTS 2022 SALES UP 13% TO €3.7 MILLION * SIGNIFICANT GROWTH ACCELERATION IN H2 2022 * ANNOUNCES TODAY 2022 SALES OF €3.7 MILLION, UP 13% COMPARED TO THE
Read More...
Hyloris: Commercial Partnership For Maxigesic® ® IV In 9 European Countries
- January 24, 2023 07:03 AM CET | Reuters
Jan 24 (Reuters) - Hyloris Pharmaceuticals SA: * HYLORIS ANNOUNCES COMMERCIAL PARTNERSHIP FOR MAXIGESIC® IV IN 9 EUROPEAN COUNTRIES * EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT SIGNED WITH SALUS
Read More...
Eurobio Scientific FY Turnover Down At 152.5 Million Euros
- January 23, 2023 05:50 PM CET | Reuters
Jan 23 (Reuters) - Eurobio Scientific SA: * 2022 TURNOVER OF EUR 152.5M * 15% CORE BUSINESS GROWTH AT EUR 93M * AT END OF 2022, EUROBIO SCIENTIFIC'S CASH POSITION WAS OVER EUR 85 MILLION, FOR A NET
Read More...
Cellectis Amends $20 Mln Convertible Note Under Collaboration Agreement With Cytovia Therapeutics
- January 20, 2023 10:32 PM CET | Reuters
Jan 20 (Reuters) - Cellectis Sa: * CELLECTIS AMENDS $20 MILLION CONVERTIBLE NOTE UNDER COLLABORATION AGREEMENT WITH ITS PARTNER CYTOVIA THERAPEUTICS * AMENDED AND RESTATED NOTE INCREASED APPLICABLE
Read More...Frequently Asked Questions
Testing
3232